Immunometabolic Reprogramming in the Bone Marrow Niche: Mechanisms, Plasticity, and Precision Therapeutic Targeting
Cell Biology International · 2026-10 · 50 (10)
DOI: 10.1002/cbin.70217 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Biology International, online erschienen am 03.10.2026. Verfasst von Adrian Khu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Universitas Methodist Indonesia, Sumatera Utara, Indonesia. Hauptthemen laut MEDLINE: Bone Marrow. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Universitas Sumatera Utara, National Research Foundation of Korea.
Abstract (Originalsprache)
The bone marrow (BM) microenvironment is increasingly recognized as a dynamic immunometabolic niche that critically governs hematologic malignancies and BM‐associated disorders, including acute myeloid leukemia (AML), multiple myeloma, myelodysplastic syndromes (MDS), metastatic infiltration, and aplastic anemia. At the core of this ecosystem, hematopoietic and leukemic stem cells (HSCs/LSCs) undergo profound immunometabolic reprogramming driven by complex interactions with stromal and immune components. Mesenchymal stromal cells (MSCs) enhance mitochondrial fitness and oxidative phosphorylation (OXPHOS) in malignant cells via cysteine supply and mitochondrial transfer, while endothelial cells regulate niche retention and survival through CXCL12 and adhesion molecules such as E‐selectin. Adipocytes further support tumor bioenergetics by supplying free fatty acids (FFAs) that fuel fatty acid oxidation (FAO), whereas M2‐polarized macrophages reinforce immunosuppressive and metabolic adaptations through arginase‐1 activity and FAO‐dependent pathways. These coordinated interactions promote a metabolically flexible phenotype characterized by shifts between OXPHOS and glycolysis, activation of FAO and glutamine metabolism, and engagement of one‐carbon metabolism, collectively sustaining malignant progression. Concurrently, the BM niche establishes a profoundly immunosuppressive milieu mediated by myeloid‐derived suppressor cells (MDSCs), regulatory T cells (Tregs), indoleamine 2,3‐dioxygenase 1 (IDO1)‐driven kynurenine signaling, lactate‐induced acidosis, and HIF‐1α‐mediated pseudo‐hypoxia, which together impair anti‐tumor immunity and facilitate disease persistence. Importantly, these immunometabolic dependencies provide actionable therapeutic vulnerabilities. Targeted strategies, including IDH1/2 inhibitors (ivosidenib and enasidenib), BCL‐2 inhibition (venetoclax), niche‐disrupting agents (plerixafor and uproleselan), OXPHOS inhibitors (IACS‐010759 and metformin), and immunometabolic interventions such as IDO1 inhibitors and CAR‐T therapies represent emerging precision approaches. Collectively, this integrative framework highlights the BM microenvironment as a central regulator of cancer cell metabolism and immune evasion, underscoring the potential of immunometabolic targeting to overcome therapeutic resistance and enable next‐generation precision medicine in hematologic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Universitas Methodist Indonesia, Sumatera Utara, Indonesia.
- Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Sumatera Utara, Indonesia.
- Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
- Department of Biology, Faculty of Mathematic and Natural Science, Universitas Sumatera Utara, Medan, Indonesia.
- Department of Orthodontics, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, Indonesia.
- Institute for Research and Community Service, State Islamic University of Sunan Kalijaga (UIN Sunan Kalijaga), Yogyakarta, Yogyakarta, Indonesia.
ORCID-Profile: Princella Halim, Amama Rani, Putri Cahaya Situmorang, Fahrul Nurkolis, Rosy Iara Maciel de Azambuja Ribeiro, Bonglee Kim, Rony Abdi Syahputra
Förderung
- Universitas Sumatera Utara
- National Research Foundation of Korea
Zitieren
APA
Khu, A., Marpaung, A. P., Halim, P., Rani, A., Situmorang, P. C., Nugraha, A. P., Nurkolis, F., de Azambuja Ribeiro, R. I. M., Kim, B., & Syahputra, R. A. (2026). Immunometabolic Reprogramming in the Bone Marrow Niche: Mechanisms, Plasticity, and Precision Therapeutic Targeting. Cell Biology International, 50(10). https://doi.org/10.1002/cbin.70217
Vancouver
Khu A, Marpaung AP, Halim P, Rani A, Situmorang PC, Nugraha AP, et al. Immunometabolic Reprogramming in the Bone Marrow Niche: Mechanisms, Plasticity, and Precision Therapeutic Targeting. Cell Biology International. 2026;50(10). doi:10.1002/cbin.70217
BibTeX
@article{Khu2026,
author = {Khu, Adrian and Marpaung, Alexander P and Halim, Princella and Rani, Amama and Situmorang, Putri Cahaya and Nugraha, Alexander Patera and Nurkolis, Fahrul and de Azambuja Ribeiro, Rosy Iara Maciel and Kim, Bonglee and Syahputra, Rony Abdi},
title = {Immunometabolic Reprogramming in the Bone Marrow Niche: Mechanisms, Plasticity, and Precision Therapeutic Targeting},
journal = {Cell Biology International},
year = {2026},
volume = {50},
number = {10},
doi = {10.1002/cbin.70217}
}
EUVIMED